Leap Therapeutics And BeiGene Announce Exclusive Option And License Agreement For DKN-01; Initiation Of Combination Studies Of Leap's DKN-01 With Beigene's Anti-PD-1 Antibody Tislelizumab Planned

Benzinga · 01/03/2020 13:56